Cargando…

Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management

Tissue-resident memory T (T(RM)) cells have emerged as key players in the immune control of melanoma. These specialized cells are identified by expression of tissue retention markers such as CD69, CD103 and CD49a with downregulation of egress molecules such as Sphingosine-1-Phosphate Receptor-1 (S1P...

Descripción completa

Detalles Bibliográficos
Autores principales: Plunkett, Kai R., Armitage, Jesse D., Inderjeeth, Andrisha-Jade, McDonnell, Alison M., Waithman, Jason, Lau, Peter K. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709277/
https://www.ncbi.nlm.nih.gov/pubmed/36466880
http://dx.doi.org/10.3389/fimmu.2022.1048758
_version_ 1784841114604273664
author Plunkett, Kai R.
Armitage, Jesse D.
Inderjeeth, Andrisha-Jade
McDonnell, Alison M.
Waithman, Jason
Lau, Peter K. H.
author_facet Plunkett, Kai R.
Armitage, Jesse D.
Inderjeeth, Andrisha-Jade
McDonnell, Alison M.
Waithman, Jason
Lau, Peter K. H.
author_sort Plunkett, Kai R.
collection PubMed
description Tissue-resident memory T (T(RM)) cells have emerged as key players in the immune control of melanoma. These specialized cells are identified by expression of tissue retention markers such as CD69, CD103 and CD49a with downregulation of egress molecules such as Sphingosine-1-Phosphate Receptor-1 (S1PR1) and the lymphoid homing receptor, CD62L. T(RM) have been shown to be integral in controlling infections such as herpes simplex virus (HSV), lymphocytic choriomeningitis virus (LCMV) and influenza. More recently, robust pre-clinical models have also demonstrated T(RM) are able to maintain melanoma in a dormant state without progression to macroscopic disease reminiscent of their ability to control viral infections. The discovery of the role these cells play in anti-melanoma immunity has coincided with the advent of immune checkpoint inhibitor (ICI) therapy which has revolutionized the treatment of cancers. ICIs that target programmed death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) have led to substantial improvements in outcomes for patients with metastatic melanoma and have been rapidly employed to reduce recurrences in the resected stage III setting. While ICIs mediate anti-tumor activity via CD8(+) T cells, the specific subsets that facilitate this response is unclear. T(RM) invariably exhibit high expression of immune checkpoints such as PD-1, CTLA-4 and lymphocyte activating gene-3 (LAG-3) which strongly implicates this CD8(+) T cell subset as a crucial mediator of ICI activity. In this review, we present pre-clinical and translational studies that highlight the critical role of T(RM) in both immune control of primary melanoma and as a key CD8(+) T cell subset that mediates anti-tumor activity of ICIs for the treatment of melanoma.
format Online
Article
Text
id pubmed-9709277
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97092772022-12-01 Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management Plunkett, Kai R. Armitage, Jesse D. Inderjeeth, Andrisha-Jade McDonnell, Alison M. Waithman, Jason Lau, Peter K. H. Front Immunol Immunology Tissue-resident memory T (T(RM)) cells have emerged as key players in the immune control of melanoma. These specialized cells are identified by expression of tissue retention markers such as CD69, CD103 and CD49a with downregulation of egress molecules such as Sphingosine-1-Phosphate Receptor-1 (S1PR1) and the lymphoid homing receptor, CD62L. T(RM) have been shown to be integral in controlling infections such as herpes simplex virus (HSV), lymphocytic choriomeningitis virus (LCMV) and influenza. More recently, robust pre-clinical models have also demonstrated T(RM) are able to maintain melanoma in a dormant state without progression to macroscopic disease reminiscent of their ability to control viral infections. The discovery of the role these cells play in anti-melanoma immunity has coincided with the advent of immune checkpoint inhibitor (ICI) therapy which has revolutionized the treatment of cancers. ICIs that target programmed death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) have led to substantial improvements in outcomes for patients with metastatic melanoma and have been rapidly employed to reduce recurrences in the resected stage III setting. While ICIs mediate anti-tumor activity via CD8(+) T cells, the specific subsets that facilitate this response is unclear. T(RM) invariably exhibit high expression of immune checkpoints such as PD-1, CTLA-4 and lymphocyte activating gene-3 (LAG-3) which strongly implicates this CD8(+) T cell subset as a crucial mediator of ICI activity. In this review, we present pre-clinical and translational studies that highlight the critical role of T(RM) in both immune control of primary melanoma and as a key CD8(+) T cell subset that mediates anti-tumor activity of ICIs for the treatment of melanoma. Frontiers Media S.A. 2022-11-16 /pmc/articles/PMC9709277/ /pubmed/36466880 http://dx.doi.org/10.3389/fimmu.2022.1048758 Text en Copyright © 2022 Plunkett, Armitage, Inderjeeth, McDonnell, Waithman and Lau https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Plunkett, Kai R.
Armitage, Jesse D.
Inderjeeth, Andrisha-Jade
McDonnell, Alison M.
Waithman, Jason
Lau, Peter K. H.
Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
title Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
title_full Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
title_fullStr Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
title_full_unstemmed Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
title_short Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
title_sort tissue-resident memory t cells in the era of (neo) adjuvant melanoma management
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709277/
https://www.ncbi.nlm.nih.gov/pubmed/36466880
http://dx.doi.org/10.3389/fimmu.2022.1048758
work_keys_str_mv AT plunkettkair tissueresidentmemorytcellsintheeraofneoadjuvantmelanomamanagement
AT armitagejessed tissueresidentmemorytcellsintheeraofneoadjuvantmelanomamanagement
AT inderjeethandrishajade tissueresidentmemorytcellsintheeraofneoadjuvantmelanomamanagement
AT mcdonnellalisonm tissueresidentmemorytcellsintheeraofneoadjuvantmelanomamanagement
AT waithmanjason tissueresidentmemorytcellsintheeraofneoadjuvantmelanomamanagement
AT laupeterkh tissueresidentmemorytcellsintheeraofneoadjuvantmelanomamanagement